Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF Summary
rhIL-28A (Catalog # 1587-IL) dilutions at 1-1000 ng/mL, the concentration of rhIL-28A that produces 50% of the optimal binding response is found to be approximately 40-200 ng/mL.
|Human IL-28 R alpha
(Arg21 - Ala228)
Accession # Q8IU57
(Pro100 - Lys330)
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in sterile PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Background: IL-28 R alpha/IFN-lambda R1
IL-28 R alpha (IL-28 receptor alpha subunit; also named interferon-lambda R1) is a type I transmembrane glycoprotein that is the cytokine receptor family 2 member 12 (CRF2-12) (1 - 4). It pairs with the IL-10 receptor beta subunit (IL-10 R beta, CRF2-4) to form the IL-28 R (1 - 4). Each subunit of this receptor can interact with the interferon-like cytokines (type III interferons) IL-28A (IFN-lambda 2), IL-28B (IFN-lambda 3) or IL-29 (IFN-lambda 1) (1 - 4). Human IL-28 R alpha cDNA encodes a 520 amino acid (aa) protein with a 20 aa signal peptide, a 208 aa extracellular domain (ECD) with a fibronectin type III motif and four potential N-glycosylation sites, a 21 aa transmembrane sequence, and a proline-rich and acidic 271 aa cytoplasmic domain. Eight isoforms have been sequenced, but their significance is unknown (3, 5). Isoforms of 211 and 244 aa appear to lack transmembrane sequences. These and other isoforms of 491, 437, 322, 283 and 184 aa have alternate N- or C-termini, or lack an internal sequence (aa 268 - 296). The mature human IL-28 R alpha ECD shares 67%, 66%, 78% and 74% aa sequence identity with mouse, rat, canine and bovine IL-28 R alpha, respectively. Some cross-species reactivity has been shown (6). IL-28 R is constitutively expressed in most tissues, but its ligands are mainly produced by antigen presenting cells in response to viruses and their products (2 - 6). Signaling through IL-28 R alpha is similar to that of receptors for type I IFNs, including tyrosine phosphorylation, activation of JAK tyrosine kinases, STAT phosphorylation and formation of the IFN-stimulated gene factor 3 (ISGF-3) transcription factor complex (1 - 7). This signaling pathway induces antiviral activity and upregulates MHC class I antigen expression (2 - 7). Anti-proliferative activity has also been shown for IL-28/IL-28 R (7).
- Chen, Q. et al. (2006) Vitam. Horm. 74:207.
- Meager, A. et al. (2005) Cytokine 31:109.
- Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
- Kotenko, S.V. et al. (2003) Nat. Immunol. 4:69.
- Entrez Accession # NP_775088, EAW95113, EAW95115, EAW95116, AAI39723, AAI01409.
- Lasfar, A. et al. (2006) Cancer Res. 66:4468.
- Dumoutier, L. et al. (2004) J. Biol. Chem. 279:32269.
Citations for Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells
Authors: DM Santer, GES Minty, DP Golec, J Lu, J May, A Namdar, J Shah, S Elahi, D Proud, M Joyce, DL Tyrrell, M Houghton
PLoS Pathog., 2020-04-30;16(4):e1008515.
Sample Types: Whole Cells
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
Authors: Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K
Genes Immun., 2009-10-01;10(8):702-14.
Sample Types: Whole Cells
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF
There are currently no reviews for this product. Be the first to review Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF and earn rewards!
Have you used Recombinant Human IL-28 R alpha/IFN-lambda R1 Fc Chimera, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image